Successful use of bivalirudin for superior vena cava recanalization and stent placement in a child with heparin-induced thrombocytopenia
JP Breinholt, BS Moffett, KM Texter, FF Ing - Pediatric cardiology, 2008 - Springer
JP Breinholt, BS Moffett, KM Texter, FF Ing
Pediatric cardiology, 2008•SpringerHeparin-induced thrombocytopenia (HIT) is a potentially life-threatening, adverse effect of
heparin therapy. Patients with this complication require an alternative approach to
anticoagulation. Bivalirudin is a direct thrombin inhibitor with an efficacy comparable to that
of heparin, a short half-life, and reduced bleeding complications in adults. We present the
case of a 2-year-old boy with HIT Type II who underwent recanalization of an occluded
superior vena cava and stent placement, utilizing bivalirudin as anticoagulant.
heparin therapy. Patients with this complication require an alternative approach to
anticoagulation. Bivalirudin is a direct thrombin inhibitor with an efficacy comparable to that
of heparin, a short half-life, and reduced bleeding complications in adults. We present the
case of a 2-year-old boy with HIT Type II who underwent recanalization of an occluded
superior vena cava and stent placement, utilizing bivalirudin as anticoagulant.
Abstract
Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening, adverse effect of heparin therapy. Patients with this complication require an alternative approach to anticoagulation. Bivalirudin is a direct thrombin inhibitor with an efficacy comparable to that of heparin, a short half-life, and reduced bleeding complications in adults. We present the case of a 2-year-old boy with HIT Type II who underwent recanalization of an occluded superior vena cava and stent placement, utilizing bivalirudin as anticoagulant.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果